Cytokinetics (CYTK) AI Stock Analysis

• Market Cap: $5.82B
• Dividend Yield: N/A
• Average Volume (3M): 2.77M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.96
• Revenue Growth: 2635.74%
• EPS Growth: 4.66%
• Country: US
• Employees: 498
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.12
• Shares Outstanding: 119,657,160
• 10 Day Avg. Volume: 2,855,391
• 30 Day Avg. Volume: 2,767,247
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.68
• Enterprise Value/Revenue: 46.01
• Enterprise Value/Gross Profit: -20.27
• Enterprise Value/Ebitda: -7.81
• 1Y Price Target: $79.57
• Price Target Upside: 64.91% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

• Rating: 55 Neutral
• Price Target: $51.00 ▲(5.70% Upside)

Cytokinetics' overall stock score is primarily impacted by its financial instability and ongoing losses, which are significant risks. However, strong technical indicators and positive corporate events provide some optimism. The company's future prospects hinge on successful regulatory approvals and commercialization of aficamten.

Positive Factors

Revenue Growth

Rapid revenue growth indicates strong demand for Cytokinetics' products and successful partnerships, enhancing long-term financial prospects.

Regulatory Progress

Positive regulatory progress in Europe and China suggests potential market expansion and increased revenue streams, strengthening future market position.

Clinical Trial Success

Successful clinical trials enhance the credibility and potential marketability of aficamten, positioning it as a leading treatment in its category.

Negative Factors

Financial Instability

Financial instability due to high leverage and negative equity can limit strategic flexibility and increase vulnerability to economic downturns.

Profitability Challenges

Ongoing net losses highlight operational inefficiencies and the need for improved cost management to achieve sustainable profitability.

Increased Expenses

Rising R&D expenses, while necessary for innovation, strain financial resources and may delay profitability if not managed effectively.

Cytokinetics Business Overview & Revenue Model

Company Description

Cytokinetics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and other therapeutics to treat debilitating diseases and medical conditions that affect muscle function. The company operates primarily in the sectors of neuromuscular diseases and cardiovascular diseases, with core products that include its lead drug candidates designed to enhance muscle contractility and improve overall muscle performance.

How the Company Makes Money

Cytokinetics generates revenue primarily through collaborations and partnerships with other pharmaceutical companies, as well as potential future sales of its drug candidates upon successful commercialization. The company engages in licensing agreements, where it may receive upfront payments, milestone payments based on clinical and regulatory progress, and royalties on future product sales. Additionally, Cytokinetics may also secure funding through grants or government programs aimed at supporting innovative research in the biopharmaceutical sector. The company's partnerships with larger pharmaceutical firms can also provide significant financial support and resources, enhancing its ability to advance its drug candidates through the development pipeline.

Cytokinetics Financial Statement Overview

Summary

Cytokinetics is experiencing rapid revenue growth but struggles with profitability and financial stability. High leverage and negative equity pose significant risks, while cash flow management shows minor improvements. The company needs to address operational inefficiencies and strengthen its balance sheet to improve its financial health.

Income Statement

Cytokinetics shows significant revenue growth in the TTM period, but profitability remains a challenge with negative gross and net profit margins. The company has consistently reported negative EBIT and EBITDA margins, indicating ongoing operational inefficiencies.

Balance Sheet

The balance sheet reflects high leverage with a negative debt-to-equity ratio due to negative stockholders' equity. Return on equity is positive but misleading due to negative equity. The equity ratio is also negative, indicating financial instability.

Cash Flow

Operating and free cash flows are negative, though there is a slight improvement in free cash flow growth. The ratios of cash flows to net income are positive, suggesting some efficiency in cash management despite overall negative cash flows.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	85.74M	18.47M	7.53M	94.59M	70.43M	55.83M
Gross Profit	-194.63M	-320.93M	-322.59M	-146.22M	-89.51M	-41.12M
EBITDA	-504.83M	-493.48M	-456.68M	-329.40M	-176.34M	-86.78M
Net Income	-606.31M	-589.53M	-526.24M	-388.95M	-215.31M	-127.29M
Balance Sheet
Total Assets	1.23B	1.40B	824.32M	1.01B	841.32M	533.80M
Cash, Cash Equivalents and Short-Term Investments	858.13M	1.08B	614.82M	782.58M	471.64M	464.06M
Total Debt	858.06M	788.68M	755.77M	749.34M	269.93M	138.94M
Total Liabilities	1.59B	1.54B	1.21B	1.12B	597.46M	420.42M
Stockholders Equity	-368.72M	-135.37M	-386.32M	-107.90M	243.86M	113.38M
Cash Flow
Free Cash Flow	-440.48M	-399.80M	-415.75M	-310.85M	-191.39M	-2.11M
Operating Cash Flow	-426.92M	-395.89M	-414.33M	-299.52M	-142.52M	8.94M
Investing Cash Flow	224.65M	-553.10M	239.25M	-262.13M	-147.78M	-196.51M
Financing Cash Flow	89.10M	930.61M	221.32M	516.17M	319.98M	234.12M

Cytokinetics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTK, the sentiment is Positive. The current price of 48.25 is above the 20-day moving average (MA) of 47.05, above the 50-day MA of 41.04, and above the 200-day MA of 41.13, indicating a bullish trend. The MACD of 2.73 indicates Positive momentum. The RSI at 56.97 is Neutral, neither overbought nor oversold. The STOCH value of 21.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CYTK.

Cytokinetics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VRNA	68 Neutral	9.14B	-103.14	0.00%	―	0.00%	34.29%
IONS	64 Neutral	9.78B	-33.14	-42.46%	―	16.04%	30.61%
AXSM	58 Neutral	5.86B	-23.17	-337.87%	―	69.83%	22.16%
CYTK	55 Neutral	$5.82B	―	435.49%	―	2635.74%	4.66%
ZLAB	52 Neutral	3.64B	-16.20	-26.84%	―	32.38%	33.47%
PCVX	50 Neutral	4.35B	-7.98	0.00%	―	0.00%	11.84%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Cytokinetics Corporate Events

Cytokinetics Highlights Aficamten Data at ESC Congress

On August 31, 2025, Cytokinetics presented new data on aficamten at the European Society of Cardiology Congress 2025, highlighting its efficacy in improving cardiac structure and function compared to metoprolol in patients with hypertrophic cardiomyopathy (HCM). The data, published in the Journal of the American College of Cardiology and Heart Rhythm, also showed that aficamten has a low incidence of atrial fibrillation and maintains a consistent safety profile, reinforcing its potential as a treatment option under FDA review.

Cytokinetics Reveals Promising MAPLE-HCM Trial Results

Cytokinetics announced the results of its MAPLE-HCM trial, presented at the European Society of Cardiology Congress 2025, showing that aficamten outperformed the standard beta-blocker metoprolol in improving exercise capacity in patients with obstructive hypertrophic cardiomyopathy (oHCM). The trial results suggest a potential shift in treatment practices, as aficamten demonstrated superior efficacy across primary and secondary endpoints, including improved functional class and reduced symptom burden, compared to metoprolol. These findings could significantly impact the company’s market positioning and offer new treatment options for oHCM patients.

Cytokinetics Appoints James M. Daly to Board

On August 19, 2025, Cytokinetics appointed James M. Daly to its Board of Directors as a Class III member, with his term expiring in 2028. Mr. Daly, determined to be independent under corporate governance guidelines, will also serve on the Compliance Committee and participate in the company’s non-employee director compensation arrangements, including stock options and restricted stock units.